Company / SG&A Expense
Tyra Biosciences, Inc. SG&A Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$24.1M
FY2024
5-year range
$2.1M / $24.1M
FY2020-FY2024
Trend
+38.3%
vs FY2023
Sector context
#193 of 213
Health Care
What the data says
Among 213 Health Care companies, Tyra Biosciences, Inc. is in the top 9% for sg&a expense. SG&A Expense has increased for 4 consecutive years, from $2M in FY2020 to $24M in FY2024.
Based on SEC 10-K filings.
$24M in FY2024 with a 3-year CAGR of +62.2%.
Increased from $16M to $24M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +62.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 213This company $24.1M Sector average $722.3M
▼
-96.7% below sector average
Key checks
Key Insights
- Tyra Biosciences, Inc.'s sg&a expense has grown for 4 consecutive years.
- 3-year CAGR of +62.2%, indicating consistent growth.
- In FY2024, sg&a expense increased 38.3% year-over-year.
- Ranks #193 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $24.1M | +38.3% |
| FY2023 | $17.4M | +9.5% |
| FY2022 | $15.9M | +181.7% |
| FY2021 | $5.7M | +169.9% |
| FY2020 | $2.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026